Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update in HIV lymphoma.

Ariela Noy1

  • 1Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. noya@mskcc.org

Current Opinion in Oncology
|August 9, 2006
PubMed
Summary

HIV-infected individuals still face a high risk of lymphoma, the most common malignancy. Advances in understanding and treating HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease are improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Blood cancer journal·2026
Same author

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Cancers·2026
Same author

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Cancers·2026

Area of Science:

  • Oncology
  • Infectious Diseases
  • Immunology

Background:

  • Individuals with Human Immunodeficiency Virus (HIV) infection face an elevated risk of malignancies, particularly lymphoma, despite effective viral control in industrialized nations.
  • Lymphoma remains the most prevalent HIV-associated malignancy in these regions, necessitating ongoing research and therapeutic advancements.

Purpose of the Study:

  • To review recent progress in understanding and managing HIV-associated non-Hodgkin's lymphoma (NHL) and Hodgkin's disease.
  • To summarize key findings in the pathophysiology and treatment of these malignancies from January 2005 to March 2006.

Main Methods:

  • Literature review of studies published between January 2005 and March 2006.
  • Synthesis of research on HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, including treatment modalities and biological insights.

Main Results:

  • HIV-associated non-Hodgkin's lymphoma remains a significant clinical challenge, even with highly active antiretroviral therapy (HAART).
  • Diffuse large B-cell lymphoma research focused on infusional therapy and rituximab, which improved response rates but increased infection risk.
  • Biological insights into HIV-associated lymphomas and Hodgkin's disease have advanced, including investigations into virological co-infections.

Conclusions:

  • Outcomes for patients with HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease are progressively improving.
  • Enhanced understanding of disease pathophysiology and novel treatment strategies are key drivers of these improved outcomes.

Related Experiment Videos